#Patient Identifier	Histology	Diagnosis Age	Sex	Smoking History	Person Cigarette Smoking History Pack Year Value	PDL1 Expression	Prior Treatment Of Cytotoxic Chemotherapy	AGENT	Administration Of Drug Weeks	Progress Free Survival (Months)	Event Type	Treatment best response	Durable Clinical Benefit	Molecular Smoking Signature	Nonsynonymous Mutation Burden	Neoantigen Burden	Total Exonic Mutation Burden
#Identifier to uniquely specify a patient.	Histology	Age at which a condition or disease was first diagnosed.	Sex	Smoking History	Numeric computed value to represent lifetime tobacco exposure defined as number of cigarettes smoked per day x number of years smoked divided by 20.	PDL1 Expression	Prior Treatment Of Cytotoxic Chemotherapy	AGENT	Administration Of Drug Weeks	Progress Free Survival (Months)	Event Type	Treatment best response	Durable Clinical Benefit	Molecular Smoking Signature	Nonsynonymous Mutation Burden	Neoantigen Burden	Total Exonic Mutation Burden
#STRING	STRING	NUMBER	STRING	STRING	NUMBER	STRING	NUMBER	STRING	NUMBER	NUMBER	STRING	STRING	STRING	STRING	NUMBER	NUMBER	NUMBER
#1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
PATIENT_ID	HISTOLOGY	AGE	SEX	SMOKING_HISTORY	SMOKING_PACK_YEARS	PDL1_EXPRESSION	PRIOR_TREATMENT_OF_CYTOTOXIC_CHEMOTHERAPY	AGENT	ADMINISTRATION_OF_DRUG_WEEKS	PFS_MONTHS	EVENT_TYPE	TREATMENT_BEST_RESPONSE	DURABLE_CLINICAL_BENEFIT	MOLECULAR_SMOKING_SIGNATURE	NONSYNONYMOUS_MUTATION_BURDEN	NEOANTIGEN_BURDEN	TOTAL_EXONIC_MUTATION_BURDEN
luad_mskcc_2015_1	NSCLC NOS	63	Female	Former	36	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 10 mg/kg)	3	8.4	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	1192	576	1732
luad_mskcc_2015_2	Adenocarcinoma	63	Female	Former	58	Strong(>or =50% membraneous staining)	3	Pembrolizumab (Dose 10 mg/kg)	3	14.7	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	746	610	1011
luad_mskcc_2015_3	Adenocarcinoma	66	Male	Current	48	Negative(<1% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	3	2.1	Progression-free Survival	POD	No durable benefit	Transversion High	626	446	992
luad_mskcc_2015_4	Adenocarcinoma	68	Female	Never	0	Weak(1-49% membraneous staining	5	Pembrolizumab (Dose 10 mg/kg)	3	8.3	Progression-free Survival	SD	Durable clinical benefit beyond 6 months	Transversion Low	507	358	914
luad_mskcc_2015_6	Adenocarcinoma	60	Female	Former	21	Strong(>or =50% membraneous staining)	1	Pembrolizumab (Dose 10 mg/kg)	3	16.6	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	473	228	622
luad_mskcc_2015_5	Adenocarcinoma	66	Male	Former	40	Unassessable	3	Pembrolizumab (Dose 10 mg/kg)	2	14.6	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	427	300	685
luad_mskcc_2015_7	Adenocarcinoma	76	Female	Never	0	Negative(<1% membraneous staining)	6	Pembrolizumab (Dose 10 mg/kg)	3	1.9	Progression-free Survival	POD	No durable benefit	Transversion Low	378	209	558
luad_mskcc_2015_8	Squamous Cell Carcinoma	57	Male	Former	39	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 2 mg/kg)	3	4	Censored	SD	Not reached 6 months follow-up	Transversion High	368	271	552
luad_mskcc_2015_9	Adenocarcinoma	57	Male	Former	80	Strong(>or =50% membraneous staining)	3	Pembrolizumab (Dose 10 mg/kg)	3	14.5	Progression-free Survival	PR	Durable clinical benefit beyond 6 months	Transversion High	324	226	494
luad_mskcc_2015_12	Adenocarcinoma	64	Female	Former	52.5	Strong(>or =50% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	3	8.1	Progression-free Survival	SD	Durable clinical benefit beyond 6 months	Transversion High	302	114	426
luad_mskcc_2015_10	Adenocarcinoma	64	Female	Current	25	Weak(1-49% membraneous staining	0	Pembrolizumab (Dose 10 mg/kg)	3	12.6	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	296	191	450
luad_mskcc_2015_13	Adenocarcinoma	56	Male	Former	37.5	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 10 mg/kg)	2	1.8	Progression-free Survival	POD	No durable benefit	Transversion High	292	90	396
luad_mskcc_2015_11	Adenocarcinoma	65	Female	Current	25	Strong(>or =50% membraneous staining)	1	Pembrolizumab (Dose 2 mg/kg)	3	4.2	Censored	PR	Not reached 6 months follow-up	Transversion High	290	208	441
luad_mskcc_2015_15	Adenocarcinoma	59	Male	Former	34	Strong(>or =50% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	3	8.4	Censored	SD	Durable clinical benefit beyond 6 months	Transversion High	244	148	341
luad_mskcc_2015_18	Adenocarcinoma	61	Female	Current	60	Strong(>or =50% membraneous staining)	6	Pembrolizumab (Dose 10 mg/kg)	3	9.8	Censored	PR	Durable clinical benefit beyond 6 months	Transversion High	228	215	326
luad_mskcc_2015_14	Adenocarcinoma	57	Female	Former	25	Strong(>or =50% membraneous staining)	1	Pembrolizumab (Dose 2 mg/kg)	3	4.4	Censored	PR	Not reached 6 months follow-up	Transversion High	223	111	342
luad_mskcc_2015_20	Adenocarcinoma	78	Female	Former	60	Strong(>or =50% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	3	10.4	Censored	PR	Durable clinical benefit beyond 6 months	Transversion Low	201	135	305
luad_mskcc_2015_19	Squamous Cell Carcinoma	68	Male	Never	0	Unassessable	2	Pembrolizumab (Dose 10 mg/kg)	3	27.3	Censored	PR	Durable clinical benefit beyond 6 months	Transversion Low	198	80	316
luad_mskcc_2015_16	Adenocarcinoma	60	Male	Never	0	Negative(<1% membraneous staining)	5	Pembrolizumab (Dose 10 mg/kg)	2	3.3	Progression-free Survival	POD	No durable benefit	Transversion Low	190	118	341
luad_mskcc_2015_21	Adenocarcinoma	59	Male	Current	15	Weak(1-49% membraneous staining	0	Pembrolizumab (Dose 10 mg/kg)	2	8.3	Progression-free Survival	SD	Durable clinical benefit beyond 6 months	Transversion High	185	100	292
luad_mskcc_2015_17	Squamous Cell Carcinoma	51	Female	Former	2.5	Negative(<1% membraneous staining)	4	Pembrolizumab (Dose 10 mg/kg)	2	3.4	Progression-free Survival	POD	No durable benefit	Transversion Low	184	50	328
luad_mskcc_2015_23	Squamous Cell Carcinoma	59	Male	Current	45	Negative(<1% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	2	1.9	Progression-free Survival	POD	No durable benefit	Transversion High	170	51	255
luad_mskcc_2015_22	Adenocarcinoma	73	Female	Former	43.75	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 10 mg/kg)	2	6.5	Progression-free Survival	SD	No durable benefit	Transversion Low	148	99	261
luad_mskcc_2015_24	Adenocarcinoma	50	Male	Never	0	Weak(1-49% membraneous staining	6	Pembrolizumab (Dose 10 mg/kg)	2	1.9	Progression-free Survival	POD	No durable benefit	Transversion Low	134	99	209
luad_mskcc_2015_26	Adenocarcinoma	49	Male	Never	0	Strong(>or =50% membraneous staining)	2	Pembrolizumab (Dose 10 mg/kg)	3	1.9	Progression-free Survival	POD	No durable benefit	Transversion Low	127	58	190
luad_mskcc_2015_25	Adenocarcinoma	63	Male	Former	73.5	Weak(1-49% membraneous staining	2	Pembrolizumab (Dose 2 mg/kg)	3	1.4	Progression-free Survival	POD	No durable benefit	Transversion Low	122	83	199
luad_mskcc_2015_28	Adenocarcinoma	62	Female	Former	6	Weak(1-49% membraneous staining	2	Pembrolizumab (Dose 2 mg/kg)	3	3.5	Progression-free Survival	SD	No durable benefit	Transversion Low	109	74	145
luad_mskcc_2015_27	Adenocarcinoma	71	Male	Former	20	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 10 mg/kg)	3	2.1	Progression-free Survival	POD	No durable benefit	Transversion Low	106	112	167
luad_mskcc_2015_29	Adenocarcinoma	56	Female	Former	8	Weak(1-49% membraneous staining	0	Pembrolizumab (Dose 10 mg/kg)	2	6.3	Progression-free Survival	SD	No durable benefit	Transversion Low	79	87	140
luad_mskcc_2015_30	Adenocarcinoma	80	Male	Former	56	Negative(<1% membraneous staining)	0	Pembrolizumab (Dose 10 mg/kg)	3	8.3	Progression-free Survival	PR	Durable clinical benefit beyond 6 months	Transversion Low	56	30	94
luad_mskcc_2015_32	Adenocarcinoma	41	Female	Current	2.25	Weak(1-49% membraneous staining	1	Pembrolizumab (Dose 10 mg/kg)	3	1.9	Progression-free Survival	POD	No durable benefit	Transversion Low	35	18	85
luad_mskcc_2015_33	Adenocarcinoma	64	Male	Former	10	Weak(1-49% membraneous staining	2	Pembrolizumab (Dose 10 mg/kg)	2	1.8	Progression-free Survival	POD	No durable benefit	Transversion Low	34	27	80
luad_mskcc_2015_31	Adenocarcinoma	71	Female	Former	0.5	Unassessable	1	Pembrolizumab (Dose 10 mg/kg)	3	4.1	Progression-free Survival	SD	No durable benefit	Transversion Low	22	11	88
luad_mskcc_2015_34	Adenocarcinoma	57	Female	Former	3.15	Unassessable	1	Pembrolizumab (Dose 10 mg/kg)	3	6.3	Progression-free Survival	SD	No durable benefit	Transversion Low	11	8	45
R7495_2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
